慢阻肺急性加重期患者接受头孢哌酮钠舒巴坦钠联合喹诺酮治疗的临床效果及对炎症因子的影响

Clinical Effect of Cefoperazone Sodium Sulbactam Sodium Combined with Quinolone for Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease and Effect on Inflammatory Factors

目的评估采用头孢哌酮钠舒巴坦钠与喹诺酮联合疗法治疗慢性阻塞性肺病急性加重的效果以及对炎症因子的影响。方法选取本院2021年3月—2022年12月收治的80例慢阻肺急性加重期患者为研究对象,按随机数字法将其设为观察组与对照组,每组40例。观察组采取头孢哌酮钠舒巴坦钠联合喹诺酮治疗,对照组单独采取头孢哌酮钠舒巴坦钠治疗,对比两组患者的治疗效果、炎症因子水平、肺功能、慢阻肺综合评估测试(CAT)评分、血气分析指标。结果观察组治疗效率明显优于对照组(P<0.05);治疗后,两组白介素-10(IL-10)水平均显著提高,肿瘤坏死因子-α(TNF-α)与C-反应蛋白(CRP)水平显著下降,且观察组各项指标变化更为显著(P<0.05);治疗后,观察组一秒用力呼气容积(FEV1)、第一秒用力呼气量在用力肺活量中所占比例(FEV1/FVC)也有显著提升,且观察组的数据表现优于对照组(P<0.05);观察组和对照组在治疗后的CAT评分都有所下降,但观察组的降幅更大(P<0.05);治疗后,观察组和对照组的氧分压(PaO_(2))均有显著提高,而二氧化碳分压(PaCO_(2))则有显著下降,且观察组的数据表现优于对照组(P<0.05)。结论联合采用孢哌酮钠舒巴坦钠与喹诺酮药物治疗慢性阻塞性肺病急性发作期患者的效果显著,能够减轻炎症反应,提升肺功能并缓解肺部不适感,且安全性及可靠性均较高,值得临床广泛应用和深入研究。

Objective To evaluate effect of combination therapy of cefoperazone sodium and sulbactam sodium with quinolone for acute exacerbation of chronic obstructive pulmonary disease and effect on inflammatory factors.Methods The paper chose 80 patients with acute exacerbation of chronic obstructive pulmonary disease(COPD)in our hospital from March 2021 to December 2022,and divided them into observation group and control group randomly,with 40 cases in each group.Observation group was treated with cefoperazone sodium and sulbactam sodium combined with quinolone,while control group with cefoperazone sodium and sulbactam sodium.Curative effect,inflammatory factor levels,lung function,comprehensive evaluation scores of chronic obstructive pulmonary disease,and blood gas analysis were compared between two groups.Results After treatment,curative effect of observation group was 97.50%,which was significantly better than 77.50%in control group,(P<0.05).After treatment,levels of IL-10 in two groups increased significantly,while levels of TNF-αand CRP decreased significantly,observation group had more significant changes in various indicators(P<0.05).Observation group had significant improvement in FEV1 and FEV1/FVC levels after treatment,data performance of observation group was better than control group(P<0.05).CAT scores of observation group and control group decreased after treatment,that of observation group was greater(P<0.05).Both observation group and control group had significant increase in PaO_(2) levels after treatment,while PaCO_(2) levels decreased significantly,data performance of observation group was better than control group(P<0.05).Conclusion Combination therapy of cefoperazone sodium and sulbactam sodium with quinolone drugs can achieve significant effect for patients with acute exacerbation of chronic obstructive pulmonary disease,can reduce inflammatory reactions,improve lung function,and alleviate lung discomfort with high safety and reliability,which is worthy of extensive clinical application and in-depth research.